In data from a pivotal phase 3 trial, EF-14, the addition of Optune to standard of care chemotherapy (temozolomide) significantly improved overall survival at two and five years in a sample of ...

Data show a three-month improvement in overall and progression-free survival for patients using Optune plus standard therapy temozolomide, compared to patients using temozolomide on its own.

Median survival in GBM following standard of care ... TTFields are administered to GBM patients using the patient-operated, home-use Optune device, which delivers alternating electric fields ...

On Tuesday the company announced the FDA approved its Optune Lua device for non-small cell lung cancer treatment. Optune Lua ...

After obtaining positive results that showed significant extension of progression-free and overall survival in newly diagnosed GBM patients treated with Optune in combination with TMZ versus TMZ ...

This trial suggested that adding on tumor-treating fields to combination chemotherapy could improve survival in patients ... to validating their thesis, and Optune in general is a bit of a laggard ...

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update ...

The company said 2024 growth was primarily driven by its launch in France and improved approval rates in the U.S., which are now reflected in ...

In 2024, we brought Optune Gio® to more than 4,000 glioblastoma ... we strive to extend survival in some of the most aggressive forms of cancer.” Financial updates for the year and fourth ...